Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Peter Vadas

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Living Beings

Rats

Concepts & Ideas

Phenomena

Hydrolysis

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Vadas Peter; Gold Milton; Perelman Boris; Liss Gary M; Lack Gideon; Blyth Thomas; Simons F Estelle R; Simons Keith J; Cass Dan; Yeung Jupiter
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
Taylor S L; Hefle S L; Bindslev-Jensen C; Atkins F M; Andre C; Bruijnzeel-Koomen C; Burks A W; Bush R K; Ebisawa M; Eigenmann P A; Host A; Hourihane J O'B; Isolauri E; Hill D J; Knulst A; Lack G; Sampson H A; Moneret-Vautrin D A; Rance F; Vadas P A; Yunginger J W; Zeiger R S; Salminen J W; Madsen C; Abbott P
A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much?
Vadas Peter; Perelman Boris
Presence of undeclared peanut protein in chocolate bars imported from Europe.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Peter Vadas (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Vadas Peter; Gold Milton; Perelman Boris; Liss Gary M; Lack Gideon; Blyth Thomas; Simons F Estelle R; Simons Keith J; Cass Dan; Yeung Jupiter
Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis.
The New England journal of medicine 2008;358(1):28-35.
2004: Taylor S L; Hefle S L; Bindslev-Jensen C; Atkins F M; Andre C; Bruijnzeel-Koomen C; Burks A W; Bush R K; Ebisawa M; Eigenmann P A; Host A; Hourihane J O'B; Isolauri E; Hill D J; Knulst A; Lack G; Sampson H A; Moneret-Vautrin D A; Rance F; Vadas P A; Yunginger J W; Zeiger R S; Salminen J W; Madsen C; Abbott P
A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much?
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2004;34(5):689-95.
2003: Vadas Peter; Perelman Boris
Presence of undeclared peanut protein in chocolate bars imported from Europe.
Journal of food protection 2003;66(10):1932-4.
2003: Vadas Peter; Perelman Boris
Activated charcoal forms non-IgE binding complexes with peanut proteins.
The Journal of allergy and clinical immunology 2003;112(1):175-9.
2002: Taylor Steve L; Hefle Susan L; Bindslev-Jensen Carsten; Bock S Allan; Burks A Wesley; Christie Lynn; Hill David J; Host Arne; Hourihane Jonathan O'b; Lack Gideon; Metcalfe Dean D; Moneret-Vautrin Denise Anne; Vadas Peter A; Rance Fabienne; Skrypec Daniel J; Trautman Thomas A; Yman Ingrid Malmheden; Zeiger Robert S
Factors affecting the determination of threshold doses for allergenic foods: how much is too much?
The Journal of allergy and clinical immunology 2002;109(1):24-30.
2001: Vadas P; Wai Y; Burks W; Perelman B
Detection of peanut allergens in breast milk of lactating women.
JAMA : the journal of the American Medical Association 2001;285(13):1746-8.
1998: Pruzanski W; Stefanski E; de Beer F C; de Beer M C; Vadas P; Ravandi A; Kuksis A
Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL.
Journal of lipid research 1998;39(11):2150-60.
1998: Pruzanski W; Stefanski E; Vadas P; McNamara T F; Ramamurthy N; Golub L M
Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.
The Journal of rheumatology 1998;25(9):1807-12.
1998: Pruzanski W; Stefanski E; Vadas P; Kennedy B P; van den Bosch H
Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors.
Biochimica et biophysica acta 1998;1403(1):47-56.
1998: Lin M K; Katz A; van den Bosch H; Kennedy B; Stefanski E; Vadas P; Pruzanski W
Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis.
Inflammation 1998;22(2):161-73.
1998: Dan P; Dagan A; Krimsky M; Pruzanski W; Vadas P; Yedgar S
Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers.
Biochemistry 1998;37(17):6199-204.
1997: Dyck E D; Vadas P
Anaphylaxis to topical bacitracin.
Allergy 1997;52(8):870-1.
1997: Pruzanski W; Stefanski E; Vadas P; Ramamurthy N S
Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.
Biochemical pharmacology 1997;53(12):1901-7.
1997: Vadas P
Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid.
Biochimica et biophysica acta 1997;1346(2):193-7.
1997: Mace S; Vadas P; Pruzanski W
Anaphylactic shock induced by intraarticular injection of methylprednisolone acetate.
The Journal of rheumatology 1997;24(6):1191-4.
1997: Vadas P; Grouix B; Stefanski E; Wloch M; Pruzanski W; Schroeder J; Gauldie J
Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.
Clinical and experimental immunology 1997;108(1):175-80.
1997: Jassal S V; Morton A R; Vadas P; Pruzanski W; Stefanski E; Pierratos A
Pro-inflammatory activity of phospholipase A2 in CAPD patients with and without peritonitis.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 1997;17(2):197-9.
1997: Pruzanski W; Kennedy B P; van den Bosch H; Stefanski E; Vadas P
Microtubule depolymerization selectively down-regulates the synthesis of proinflammatory secretory nonpancreatic phospholipase A2.
Laboratory investigation; a journal of technical methods and pathology 1997;76(2):171-8.
1996: Lin M K; Farewell V; Vadas P; Bookman A A; Keystone E C; Pruzanski W
Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients.
The Journal of rheumatology 1996;23(7):1162-6.
1996: Vadas P; Stefanski E; Wloch M; Grouix B; Van Den Bosch H; Kennedy B
Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells.
European journal of biochemistry / FEBS 1996;235(3):557-63.
1995: Pruzanski W; Bogoch E; Katz A; Wloch M; Stefanski E; Grouix B; Sakotic G; Vadas P
Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes.
The Journal of rheumatology 1995;22(11):2114-9.
1995: Pruzanski W; Urowitz M B; Grouix B; Vadas P
Induction of TNF-alpha and proinflammatory secretory phospholipase A2 by intravenous administration of CAMPATH-1H in patients with rheumatoid arthritis.
The Journal of rheumatology 1995;22(10):1816-9.
1995: Pruzanski W; de Beer F C; de Beer M C; Stefanski E; Vadas P
Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2.
The Biochemical journal 1995;309 ( Pt 2)():461-4.
1995: Vadas P; Stefanski E; Grouix B; Schouten B D; Pruzanski W
Inhibition of human group II phospholipase A2 by C-reactive protein in vitro.
Journal of lipid mediators and cell signalling 1995;11(2):187-200.
1994: Pruzanski W; Albin-Cook K; Laxer R M; MacMillan J; Stefanski E; Vadas P; Silverman E D
Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity.
The Journal of rheumatology 1994;21(10):1951-4.
1994: Pruzanski W; Goulding N J; Flower R J; Gladman D D; Urowitz M B; Goodman P J; Scott K F; Vadas P
Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity.
The Journal of rheumatology 1994;21(2):252-7.
1993: Vadas P; Taylor T E; Chimsuku L; Goldring D; Stefanski E; Pruzanski W; Molyneux M E
Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.
The American journal of tropical medicine and hygiene 1993;49(4):455-9.
1993: Vadas P; Schouten B D; Stefanski E; Scott K; Pruzanski W
Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication.
Critical care medicine 1993;21(7):1087-91.
1993: Ellies L G; Heersche J N; Pruzanski W; Vadas P; Aubin J E
The role of phospholipase A2 in interleukin-1 alpha-mediated inhibition of mineralization of the osteoid formed by fetal rat calvaria cells in vitro.
Journal of dental research 1993;72(1):18-24.
1992: Pruzanski W; Mackensen A; Engelhardt R; Stefanski E; Vadas P
Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):242-6.
1992: Pruzanski W; Wilmore D W; Suffredini A; Martich G D; Hoffman A G; Browning J L; Stefanski E; Sternby B; Vadas P
Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin.
Inflammation 1992;16(5):561-70.
1992: Pruzanski W; Scott K; Smith G; Rajkovic I; Stefanski E; Vadas P
Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids.
Inflammation 1992;16(5):451-7.
1992: Vadas P; Keystone J; Stefanski E; Scott K; Pruzanski W
Induction of circulating group II phospholipase A2 expression in adults with malaria.
Infection and immunity 1992;60(9):3928-31.
1992: Pruzanski W; Greenwald R A; Street I P; Laliberte F; Stefanski E; Vadas P
Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline.
Biochemical pharmacology 1992;44(6):1165-70.
1992: Vadas P; Scott K; Smith G; Rajkovic I; Stefanski E; Schouten B D; Singh R; Pruzanski W
Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock.
Life sciences 1992;50(11):807-11.
1991: Vadas P; Pruzanski W; Farewell V
A predictive model for the clearance of soluble phospholipase A2 during septic shock.
The Journal of laboratory and clinical medicine 1991;118(5):471-5.
1991: Ellies L G; Heersche J N; Vadas P; Pruzanski W; Stefanski E; Aubin J E
Interleukin-1 alpha stimulates the release of prostaglandin E2 and phospholipase A2 from fetal rat calvarial cells in vitro: relationship to bone nodule formation.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1991;6(8):843-50.
1991: Vadas P; Pruzanski W; Stefanski E; Ellies L G; Aubin J E; Sos A; Melcher A
Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action.
Immunology letters 1991;28(3):187-93.
1991: Pruzanski W; Saito S; Stefanski E; Vadas P
Comparison of group I and II soluble phospholipases A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes.
Inflammation 1991;15(2):127-35.
1991: Pruzanski W; Bogoch E; Wloch M; Vadas P
The role of phospholipase A2 in the physiopathology of osteoarthritis.
The Journal of rheumatology. Supplement 1991;27():117-9.
1991: Pruzanski W; Bogoch E; Stefanski E; Wloch M; Vadas P
Enzymatic activity and distribution of phospholipase A2 in human cartilage.
Life sciences 1991;48(25):2457-62.
1990: Pruzanski W; Bogoch E; Stefanski E; Wloch M; Vadas P
Synthesis and release of phospholipase A2 by unstimulated human articular chondrocytes.
The Journal of rheumatology 1990;17(10):1386-91.
1990: Pruzanski W; Lee P; Stefanski E; Sternby B; Vadas P
Hypophospholipasemia A2 in systemic sclerosis.
The Journal of rheumatology 1990;17(9):1182-6.
1990: Vadas P; Pruzanski W; Stefanski E; Sternby B
Compartmental heterogeneity of soluble phospholipases A.
Inflammation 1990;14(2):173-83.
1989: Seilhamer J J; Plant S; Pruzanski W; Schilling J; Stefanski E; Vadas P; Johnson L K
Multiple forms of phospholipase A2 in arthritic synovial fluid.
Journal of biochemistry 1989;106(1):38-42.
1989: Seilhamer J J; Pruzanski W; Vadas P; Plant S; Miller J A; Kloss J; Johnson L K
Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid.
The Journal of biological chemistry 1989;264(10):5335-8.
1989: Vadas P; Pruzanski W; Kim J; Fornasier V
The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2.
The American journal of pathology 1989;134(4):807-11.
1988: Pruzanski W; Vadas P
Secretory synovial fluid phospholipase A2 and its role in the pathogenesis of inflammation in arthritis.
The Journal of rheumatology 1988;15(11):1601-3.
1988: Pruzanski W; Keystone E C; Sternby B; Bombardier C; Snow K M; Vadas P
Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis.
The Journal of rheumatology 1988;15(9):1351-5.
1988: Vadas P; Pruzanski W; Stefanski E
Extracellular phospholipase A2: causative agent in circulatory collapse of septic shock?
Agents and actions 1988;24(3-4):320-5.
1988: Vadas P; Pruzanski W; Stefanski E; Ruse J; Farewell V; McLaughlin J; Bombardier C
Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study.
The Journal of laboratory and clinical medicine 1988;111(5):584-90.
1988: Vadas P; Pruzanski W; Stefanski E; Sternby B; Mustard R; Bohnen J; Fraser I; Farewell V; Bombardier C
Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse.
Critical care medicine 1988;16(1):1-7.
1988: Pruzanski W; Vadas P; Kim J; Jacobs H; Stefanski E
Phospholipase A2 activity associated with synovial fluid cells.
The Journal of rheumatology 1988;15(5):791-4.
1986: Vadas P; Stefanski E; Pruzanski W
Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock.
Agents and actions 1986;19(3-4):194-202.
1986: Stefanski E; Pruzanski W; Sternby B; Vadas P
Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis.
Journal of biochemistry 1986;100(5):1297-303.
1986: Vadas P; Stefanski E; Pruzanski W
Influence of plasma proteins on activity of proinflammatory enzyme phospholipase A2.
Inflammation 1986;10(2):183-93.
1986: Pruzanski W; Vadas P; Fornasier V
Inflammatory effect of intradermal administration of soluble phospholipase A2 in rabbits.
The Journal of investigative dermatology 1986;86(4):380-3.
1985: Pruzanski W; Vadas P; Stefanski E; Urowitz M B
Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme.
The Journal of rheumatology 1985;12(2):211-6.
1985: Vadas P; Stefanski E; Pruzanski W
Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid.
Life sciences 1985;36(6):579-87.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Peter Vadas

Research Profile (preview)

Chemicals & Drugs

Anatomy

Disorders

Living Beings

Concepts & Ideas

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Peter Vadas (preview)

All Publications